NanoString Technologies Inc (NSTG)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:NanoString Technologies Inc (NSTG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014008
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NanoString Technologies Inc (NanoString) is a provider of life science products and tools for translational research and molecular diagnostics. The company’s products portfolio includes sprint profiler, Dx analysis system with flex, MAX analysis system, protein assays, solid tumor assays, gene fusion panels, RNA panels, DNA assays, immunology panel, gene expression codesets, pancancer immune profiling and pathways among others. NanoString’s nCounter analysis system provides cost-effective method to profile hundreds of miRNA, miRGE or DNA molecules simultaneously employing digital molecular barcoding technology. The company sells its products through direct sales force and distributors in the US, Europe, the Middle East and Asia-Pacific. NanoString is headquartered in Seattle, Washington, the US.

NanoString Technologies Inc (NSTG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
NanoString Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
NanoString Technologies Inc, Medical Devices Deals, 2011 to YTD 2017 10
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
NanoString Technologies Raises US$0.2 Million In Venture Financing 13
NanoString Technologies Raises US$15 Million In Series E Financing 14
NanoString Technologies To Raise US$0.65 Million In Venture Financing 16
NanoString Technologies Secures US$20 Million In Series D Financing 17
NanoString Technologies Secures US$2.5 Million In Venture Financing 18
Partnerships 19
NanoString Technologies Enters into Agreement with OHSU Knight Cancer Institute 19
NanoString Enters into Research Agreement with CITN for Novel Cancer Immunotherapies 20
NanoString Enters into Co-Development Agreement with Celgene 21
NanoString Technologies And BD Biosciences Enter Into Agreement To Develop Single Cell Isolation And Analysis Workflow 22
Licensing Agreements 23
NanoString Technologies Enters Into Option For Licensing Agreement With Massachusetts General Hospital 23
Equity Offering 24
NanoString Technologies Plans to Raise USD100 Million in Public Offering of Shares 24
NanoString Technologies Completes Public Offering Of Shares For US$55 Million 25
NanoString Technologies Completes IPO Of Shares For US$54 Million 27
NanoString Technologies Inc – Key Competitors 29
NanoString Technologies Inc – Key Employees 30
NanoString Technologies Inc – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
May 04, 2017: NanoString Technologies Releases Operating Results for First Quarter of 2017 32
Mar 01, 2017: NanoString Technologies Releases Fourth Quarter and Full Year 2016 Operating Results and Provides 2017 Outlook 33
Jan 10, 2017: NanoString Technologies Provides Preliminary Operational and Financial Results for 2016 34
Nov 02, 2016: NanoString Technologies Releases Operating Results for Third Quarter of 2016 35
Aug 03, 2016: NanoString Technologies Releases Operating Results for Second Quarter of 2016 36
May 05, 2016: NanoString Technologies Releases Operating Results for First Quarter of 2016 37
Feb 29, 2016: NanoString Technologies Releases Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Outlook 38
Jan 10, 2016: NanoString Technologies Provides Preliminary Operational and Financial Results for 2015 40
Corporate Communications 41
May 10, 2017: NanoString Appoints Elisha W. Finney to Board of Directors 41
Sep 13, 2016: NanoString Technologies Appoints Kirk Malloy, Ph.D. to Board of Directors 42
Product News 43
Oct 19, 2016: NanoString Technologies Presents Update on Hyb & Seq Next-Generation Sequencing Chemistry at ASHG Annual Meeting 43
Apr 03, 2017: Digital Spatial Profiling Technology Enables Quantitative Protein Profiling in FFPE Tissue Providing Detailed Molecular Characterization of Immune Response to Tumors 45
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
NanoString Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
NanoString Technologies Inc, Deals By Therapy Area, 2011 to YTD 2017 9
NanoString Technologies Inc, Medical Devices Deals, 2011 to YTD 2017 10
NanoString Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
NanoString Technologies Raises US$0.2 Million In Venture Financing 13
NanoString Technologies Raises US$15 Million In Series E Financing 14
NanoString Technologies To Raise US$0.65 Million In Venture Financing 16
NanoString Technologies Secures US$20 Million In Series D Financing 17
NanoString Technologies Secures US$2.5 Million In Venture Financing 18
NanoString Technologies Enters into Agreement with OHSU Knight Cancer Institute 19
NanoString Enters into Research Agreement with CITN for Novel Cancer Immunotherapies 20
NanoString Enters into Co-Development Agreement with Celgene 21
NanoString Technologies And BD Biosciences Enter Into Agreement To Develop Single Cell Isolation And Analysis Workflow 22
NanoString Technologies Enters Into Option For Licensing Agreement With Massachusetts General Hospital 23
NanoString Technologies Plans to Raise USD100 Million in Public Offering of Shares 24
NanoString Technologies Completes Public Offering Of Shares For US$55 Million 25
NanoString Technologies Completes IPO Of Shares For US$54 Million 27
NanoString Technologies Inc, Key Competitors 29
NanoString Technologies Inc, Key Employees 30

★海外企業調査レポート[NanoString Technologies Inc (NSTG)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Electra Private Equity plc (ELTA):企業の財務・戦略的SWOT分析
    Electra Private Equity plc (ELTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Abaxis Inc:医療機器:M&Aディール及び事業提携情報
    Summary Abaxis Inc (Abaxis) is a provider of technology, tools and services for wide range of medical applications for human and veterinary patient-care. The company focuses on development, manufacture, and marketing of portable blood analysis systems. Its portfolio encompasses patented products inc …
  • Brooks MacDonald Group PLC (BRK):企業の財務・戦略的SWOT分析
    Brooks MacDonald Group PLC (BRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • UniCredit S.p.A:戦略・SWOT・企業財務分析
    UniCredit S.p.A - Strategy, SWOT and Corporate Finance Report Summary UniCredit S.p.A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • University of California Los Angeles-製薬・医療分野:企業M&A・提携分析
    Summary University of California Los Angeles (UCLA) a subsidiary of University of California is an educational service provider that offers undergraduate education, graduate, professional education and continuing education. The university’s services include support services, campus services, graduat …
  • MEDICREA Group (ALMED):医療機器:M&Aディール及び事業提携情報
    Summary MEDICREA Group (MEDICREA) is a medical equipment company that provides surgical solutions to neurosurgeons and orthopedic surgeons. The company designs, manufactures and distributes proprietary technologies related to patient specific spinal surgery. It offers products such as polyaxial spin …
  • HSN, Inc.:企業の戦略・SWOT・財務情報
    HSN, Inc. - Strategy, SWOT and Corporate Finance Report Summary HSN, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Deutsche Telekom AG (DTE):企業の財務・戦略的SWOT分析
    Deutsche Telekom AG (DTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Croda International Plc (CRDA):企業の財務・戦略的SWOT分析
    Croda International Plc (CRDA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Gilead Sciences Inc (GILD):医療機器:M&Aディール及び事業提携情報
    Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency …
  • Bajaj Electricals Ltd. (BAJAJELEC):企業の財務・戦略的SWOT分析
    Bajaj Electricals Ltd. (BAJAJELEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Rio Grande Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Rio Grande Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • The Centre of Excellence for Prevention of Organ Failure:医療機器:M&Aディール及び事業提携情報
    Summary The Centre of Excellence for Prevention of Organ Failure (PROOF Centre) is a healthcare center that provides blood-based biomarker tests. The center conducts biomarker programs to develop simple blood tests for transplant patients and patients with chronic organ disease and biomarkers in tra …
  • Selective Insurance Group, Inc. (SIGI):企業の財務・戦略的SWOT分析
    Selective Insurance Group, Inc. (SIGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Al-Nisr Al Arabi Insurance Company:企業の戦略・SWOT・財務情報
    Al-Nisr Al Arabi Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Al-Nisr Al Arabi Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Knoll Inc (KNL):企業の財務・戦略的SWOT分析
    Knoll Inc (KNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • iNova Pharmaceuticals (Australia) Pty Ltd:企業の戦略的SWOT分析
    iNova Pharmaceuticals (Australia) Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Second Military Medical University-医療機器分野:企業M&A・提携分析
    Summary Second Military Medical University (SMMU), subsidiary of Logistic Support Department of the Central Military Commission, formerly known as Medical College of the East China Military Commanding Region is an educational service provider that provides training, and research services. The univer …
  • CVS Health Corp (CVS):製薬・医療:M&Aディール及び事業提携情報
    Summary CVS Health Corporation (CVS) is an integrated prescription and related health services provider. The company offers a range of solutions such as prescription medications; health care products; popular beauty, health and personal care brands; retail-based health clinical services; and pharmac …
  • Vitasoy International Holdings Ltd (0345)
    Vitasoy International Holdings Ltd (0345) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company

◆H&Iグローバルリサーチ株式会社のお客様(例)◆